Deciphera Pharmaceuticals is committed to advancing improved treatments for patients with cancer. Our pipeline of tumor-targeted therapies and immuno-targeted therapies are being evaluated for the treatment of multiple cancer indications including:
Gastrointestinal stromal tumors (GIST) are tumors in the gastrointestinal tract, most commonly in the stomach or small intestine. GIST tumors are predominantly driven by KIT kinase mutations. Approximately 6,700 – 19,000 patients in the U.S., Europe and Japan are diagnosed with GIST tumors annually.
Systemic mastocytosis is a disorder where mast cells (immune cells) are abnormally increased in multiple organs including the bone marrow. Mastocytosis has been associated with a primary mutation in KIT exon 17. Approximately 6,700 patients in the U.S., Europe and Japan are diagnosed with systemic mastocytosis annually.
American Cancer Society